Trial Profile

A Phase 2 trial of intravenous CBD Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 18 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Cerebral ischaemia
Focus Therapeutic Use

Most Recent Events

16 Feb 2021 According to a GW Pharmaceuticals media release, the trial is expected to commence in Q1 2021.
11 May 2020 According to a GW Pharmaceuticals media release,Start of new clinical programs delayed until H2 2020 due to current COVID restrictions
27 Nov 2018 According to a GW Pharmaceuticals media release, the company expects to start this study in H1 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com